Source: CureToday articles
Younger patients with lung cancer are more likely to have mutations that allow for targeted therapies, which can lead to more personalized and effective treatment.
Recent Content
- Self-Care for Women’s Health
- Pharmacist Involvement in Clinical Research and the FINEARTS-HF Trial
- With Cancer in Remission, What Is the New Normal for Patients?
- Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation
- Study Reveals Safety and Effectiveness of RSV Vaccine for Older Adults
- Younger Patients With Lung Cancer Often Have Targetable Biomarkers
- First Nationwide Seroprevalence Study of HDV in the US Offers Prevalence of HDV Among HBsAg-Positive Specimens
- Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care
- Facing Cancer as an AYA and Navigating Fertility Preservation Choices
- What Patients Should Know About a Melanoma Diagnosis